FILE PHOTO: An Astra Zeneca logo is pictured in Brussels, Belgium March 4, 2024. REUTERS/Yves Herman/File Photo April 20 (Reuters) - AstraZeneca ‌said ‌on Monday its experimental treatment tozorakimab ...

(Alliance News) - AstraZeneca PLC on Friday reported positive phase-three trial results for its chronic obstructive pulmonary disease treatment tozorakimab. The Cambridge, England-based pharmaceutical ...

Britain's most valuable company said its experimental lung disease medicine met its target in two late-stage clinical trials. The respiratory treatment Tozorakimab, reduced flare-ups of chronic ...

Unlock powerful investing tools and data-driven insights with TipRanks Premium for more confident investment decisions. Discover top stock picks and new investment opportunities through TipRanks' ...

AstraZeneca executives say they are “not worried” that the failure of tozorakimab in a phase 2 chronic obstructive pulmonary disease (COPD) trial will throw their plans for the anti-IL-33 monoclonal ...

First-ever IL-33-targeting biologic to demonstrate statistically significant and highly clinically meaningful reductions in COPD exacerbations in two replicate Phase III clinical trials WILMINGTON, ...

Third positive pivotal Phase III clinical trial of AstraZeneca’s IL-33-targeting biologic further demonstrates its benefits in COPD Positive high-level results from the pivotal Phase III MIRANDA trial ...